ArthroCare Receives FDA Clearance for Parallax Contour-enhanced Vertebral Augmentation Device

ArthroCare Corp. (NASDAQ: ARTC) announced today that it has received clearance from the U.S. Food and Drug Administration to market its second-generation Parallax® Contour® -enhanced Vertebral Augmentation Device specifically for void creation in a vertebral body followed by injection of bone cement. Vertebral augmentation, also referred to as vertebroplasty or kyphoplasty, is commonly used to treat painful vertebral compression fractures. This new lower profile device makes it easier for surgeons to operate in tight spaces and to provide additional tactile and audible feedback to improve ease of use during the void creation process.